FDA requests more testing on Novartis' Galvus

01/17/2008 | Wall Street Journal (free content), The

The FDA has asked Swiss drugmaker Novartis AG to conduct more clinical tests on Galvus, its treatment for diabetes. The drug, already approved in Europe and other markets, was expected to be launched in the U.S. last year. Novartis is still in talks with the FDA, but may stop seeking agency approval if the requirements become too burdensome, chief executive David Vasella said.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC